67 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
on a country-by-country and product-by-product basis.
We are solely responsible for the development and commercialization of the product candidates licensed … of China, including Hong Kong and Macau. Yuyuan will be responsible for the continued development of nolasiban in China at its sole cost
10-K
2022 FY
EX-10.20
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
be responsible, at Buyer’s expense, for filing the Assignment, and other documents, certificates, and instruments of conveyance with the applicable
10-K
2022 FY
EX-31.1
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. I am responsible for establishing
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
Section 7.01
Certain Duties and Responsibilities of Trustee
Section 7.02
Certain Rights of Trustee
Section 7.03
Trustee Not Responsible for Recitals … shall be deemed to evidence the same debt as the lost, destroyed or stolen Security.
“Responsible Officer” when used with respect to the Trustee
UPLOAD
OBSVF
ObsEva SA
9 Dec 22
Letter from SEC
12:00am
refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
that the company and its management are responsible
6-K
EX-99.1
woar5na
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
424B7
idfxa mz24g
3 Mar 22
Prospectus with selling stockholder info
4:43pm
UPLOAD
i0kzdc ql
23 Feb 22
Letter from SEC
12:00am
F-3
y8bsfm08urv w36ng
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.3
nfjhb
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
424B7
k86pdc
23 Nov 21
Prospectus with selling stockholder info
4:06pm
6-K
EX-99.2
iyw3egxbbfpjk3
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
UPLOAD
l6ipggd khg
17 Nov 21
Letter from SEC
12:00am
F-3
v3zpmlfvkb601a
10 Nov 21
Shelf registration (foreign)
5:23pm